Torthaí cuardaigh - Sang‐We Kim

Beachtaigh na torthaí
  1. 1
    Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2

    Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2 de réir Patrick Lécine, Joseph E. Italiano, Sang‐We Kim, Jean‐Luc Villeval, Ramesh A. Shivdasani

    Foilsithe / Cruthaithe 2000
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

    ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences de réir İrfan Çiçin, Claudio Martín, Carolina Kawamura Haddad, Sang‐We Kim, Alexey Smolin, Arif Abdillah, Xue Yang

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis

    Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis de réir Harald Schulze, Manav Korpal, Jonathan Hurov, Sang-We Kim, Jinghang Zhang, Lewis C. Cantley, Thomas Graf, Ramesh A. Shivdasani

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor

    Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor de réir Mi-Woo Lee, Chul-Won Seo, Sang‐We Kim, Hwa-Jeong Yang, Hae‐Woong Lee, Jee‐Ho Choi, Kee‐Chan Moon, Jai‐Kyoung Koh

    Foilsithe / Cruthaithe 2003
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

    Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy de réir Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong Seok Lee, Sang Won Shin, Jin Hyoung Kang, Myung‐Ju Ahn, Jin Seok Ahn, Cheolwon Suh, Sang-We Kim

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung

    [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung de réir Hee-Jung Sohn, You-Jung Yang, Jin‐Sook Ryu, Seung Jun Oh, Ki Chun Im, Dae Hyuk Moon, Dae Ho Lee, Cheolwon Suh, Jung‐Shin Lee, Sang‐We Kim

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

    Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer de réir Wonjun Ji, Chang‐Min Choi, Jin Kyung Rho, Se Jin Jang, Young Soo Park, Sung‐Min Chun, Woo Sung Kim, Jung‐Shin Lee, Sang‐We Kim, Dae Ho Lee, Jae Cheol Lee

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

    First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non... de réir Keunchil Park, Chong‐Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Chun-Ming Tsai, Jong-Seok Lee, Jin Hyoung Kang, K.C. Chan, Pablo Ernesto Pérez, Peter Button, Myung‐Ju Ahn, Tony Mok

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer de réir Ben Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong‐Wan Kim, Laura Q.M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti, Don L. Gibbons

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

    Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations de réir Alessandra Bearz, Jean‐François Martini, Jacek Jassem, Sang‐We Kim, Gee‐Chen Chang, Alice T. Shaw, D A Shepard, E. Dall’O’, Anna Polli, Holger Thurm, Gérard Zalcman, M.R. García Campelo, Konstantin Penkov, Hidetoshi Hayashi, Benjamin Solomon

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report de réir Dong‐Wan Kim, Sang‐We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee‐Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar, Suresh S. Ramalingam

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer de réir Enriqueta Felip, Fabrice Barlési, Benjamin Besse, Quincy Chu, Leena Gandhi, Sang‐We Kim, Enric Carcereny, Lecia V. Sequist, Paal Brunsvig, C. Chouaïd, Egbert F. Smit, Harry J.M. Groen, Dong‐Wan Kim, Keunchil Park, Emin Avşar, Sebastian Szpakowski, Mikhail Akimov, Edward B. Garon

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study de réir James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer de réir Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang‐We Kim, James Chih‐Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, M.R. García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao Mark Lin, Minal Mehta, Pasi A. Jänne

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 de réir Byoung Chul Cho, Ji‐Youn Han, Ki Hyeong Lee, Yun‐Gyoo Lee, Dong‐Wan Kim, Young Joo Min, Sang‐We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Sung Sook Lee, NaMi Lee, Jang Young Wang, Hyejoo Park, Myung‐Ju Ahn

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

    Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial de réir Benjamin Solomon, Ibiayi Dagogo‐Jack, Se-Hoon Lee, Michael Boyer, Suresh S. Ramalingam, Enric Carcereny, Enriqueta Felip, Ji‐Youn Han, Toyoaki Hida, Brett Hughes, Sang‐We Kim, Makoto Nishio, Takashi Seto, Tatsuro Okamoto, Xiaoxi Zhang, Jean‐François Martini, Erjian Wang, Steven De Beukelaer, Todd M. Bauer

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

    Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01) de réir Jong‐Mu Sun, Ki Hyeong Lee, Sang‐we Kim, Dae Ho Lee, Young Joo Min, Hwan‐Jung Yun, Hoon Kyo Kim, Hong Song, Yeul Hong Kim, Bong‐Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Won Jae Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

    ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearr... de réir Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz, Scott A. Laurie, Mark J. McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen A. Osborne, Wen Gu, Jeffrey W. Scott, Vanessa Q. Passos, Yvonne Lau, Anna Wrona

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study

    Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study de réir Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans, Maja J.A. de Jonge, Sang‐We Kim, Marie Meurer, Sophie Postel‐Vinay, Jong Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) de réir Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medić, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok, Melissa L. Johnson

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: